PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023.
| मुख्य लेखक: | |
|---|---|
| अन्य लेखक: | |
| स्वरूप: | थीसिस |
| भाषा: | English |
| प्रकाशित: |
Brac University
2024
|
| विषय: | |
| ऑनलाइन पहुंच: | http://hdl.handle.net/10361/23252 |
| id |
10361-23252 |
|---|---|
| record_format |
dspace |
| spelling |
10361-232522024-06-09T21:02:54Z PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment Lubaba, Anikah Fariha, Luluel Maknun School of Pharmacy, Brac University Cardiovascular disease CVD Cholesterol-lowering therapy Hyperlipidemia Monoclonal antibody PCSK9 Heart--Diseases--Treatment Coronary heart disease--Treatment Cholesterol--Pathophysiology This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. Cataloged from the PDF version of thesis. Includes bibliographical references (pages 19-24). One of the largest global causes of morbidity and mortality is cardiovascular disease (CVD). Elevated low-density lipoprotein (LDL) levels and adverse cardiovascular outcomes are linked to increased levels of the proprotein convertase subtilisin/kexin type 9 (PCSK9) in the blood. Inhibiting PCSK9 lowers the levels of circulating LDL-C by increasing the extracellular membrane density of LDL receptors. Regulators have approved the use of PCSK9 antibodies to treat patients with high LDL-cholesterol (LDL-C) levels. It can reduce LDL-C in patients receiving statin therapy by as much as 60% with clinical advantages, such as lower incidence of myocardial infarction or stroke. The outcomes of the major clinical trials, ODYSSEY and the FOURIER indicated a statistically significant decrease in mortality with a relative risk reduction of 15% in both trials. Two monoclonal antibodies (evolocumab and alirocumab) are PCSK9 inhibitors approved by the FDA for the treatment of familial hypercholesterolaemia, and patients who require additional therapies along with healthy diet and statin medication. Anikah Lubaba B. Pharmacy 2024-06-09T06:32:54Z 2024-06-09T06:32:54Z ©2023 2023-02 Thesis ID: 19146073 http://hdl.handle.net/10361/23252 en Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. 36 pages application/pdf Brac University |
| institution |
Brac University |
| collection |
Institutional Repository |
| language |
English |
| topic |
Cardiovascular disease CVD Cholesterol-lowering therapy Hyperlipidemia Monoclonal antibody PCSK9 Heart--Diseases--Treatment Coronary heart disease--Treatment Cholesterol--Pathophysiology |
| spellingShingle |
Cardiovascular disease CVD Cholesterol-lowering therapy Hyperlipidemia Monoclonal antibody PCSK9 Heart--Diseases--Treatment Coronary heart disease--Treatment Cholesterol--Pathophysiology Lubaba, Anikah PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| description |
This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. |
| author2 |
Fariha, Luluel Maknun |
| author_facet |
Fariha, Luluel Maknun Lubaba, Anikah |
| format |
Thesis |
| author |
Lubaba, Anikah |
| author_sort |
Lubaba, Anikah |
| title |
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| title_short |
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| title_full |
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| title_fullStr |
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| title_full_unstemmed |
PCSK9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| title_sort |
pcsk9i: proprotein convertase subtilisin/kexin type 9 inhibitor a new phase of lipid-lowering treatment |
| publisher |
Brac University |
| publishDate |
2024 |
| url |
http://hdl.handle.net/10361/23252 |
| work_keys_str_mv |
AT lubabaanikah pcsk9iproproteinconvertasesubtilisinkexintype9inhibitoranewphaseoflipidloweringtreatment |
| _version_ |
1814308342958391296 |